Leiomyosarcoma

Watchlist

(log in to enable)

Retrieved

2021-01-23

Source

Orphanet

Trials

—

Genes

USP18, HMGA1, PTGS2, CSF3, DMD, CHEK2, MED12, TP53, KIT, CDKN2A, MDM2, IGF2, BCL2, TP63, PIK3CA, MYC, H3P10, PIK3CB, PIK3CD, PTEN, FH, ESR1, CD274, PIK3CG, ALK, VCAN, MYOCD, HMGA2, CALD1, HHAT

USP18, HMGA1, PTGS2, CSF3, DMD, CHEK2, MED12, TP53, KIT, CDKN2A, MDM2, IGF2, BCL2, TP63, PIK3CA, MYC, H3P10, PIK3CB, PIK3CD, PTEN, FH, ESR1, CD274, PIK3CG, ALK, VCAN, MYOCD, HMGA2, CALD1, HHAT, AKT1, SERPINE1, HTC2, BRCA1, IGF1, ATM, HDAC9, CDH1, CD163, PGR, ABCB1, SMUG1, RRAS2, PRUNE2, ACTB, AXL, VIM, CTNNB1, ZEB1, MIR200C, TYRO3, DFFB, SNAI2, DES, TOPBP1, NDC80, VDR, FERMT2, RASSF1, EDIL3, TP73, AGTR2, AGTR1, TP53BP1, TPX2, ARL4C, IFITM1, VEGFA, IRS2, MVP, DLEC1, ZEB2, VIPR2, CCDC6, KLF4, SLC33A1, COIL, LATS1, SOCS3, SLC25A11, PEG10, PDCD4, TBC1D9, RFTN1, NACC1, AZIN2, RICTOR, CHAMP1, GADL1, RTL1, MIR10A, MIR125A, MIR152, MIR21, MIR221, MIR34C, MIR93, GGTLC5P, SSX2B, GGTLC3, GGT2, GGTLC4P, PGR-AS1, WDR20, MYLK3, MYLK2, BCOR, ZNF281, LMOD1, TOP2A, PARP1, LEF1, UBASH3A, MOV10L1, FBLIM1, ANO1, TRIM63, RCBTB1, SMARCAD1, PNPLA2, WDR48, PRUNE1, ZNF250, FERMT3, OBSCN, AMHR2, CDO1, TNS1, GAS6, F3, ACSL4, FASN, FCGR3A, FCGR3B, FGF2, FOLH1, FUS, GGT1, CDH2, GLI1, GRN, HIF1A, CD68, HMMR, HSP90AA1, CD34, IL1R1, EWSR1, ERCC5, TERT, DDIT3, CHGA, COL1A1, CR2, CSF1, CDK8, NKX2-5, DAP, DCC, DFFA, EPHB2, DHCR24, CDK4, DPEP1, E2F1, EGF, EGFR, ELN, SLC29A1, CXCL8, INSRR, ITGA7, TSPAN31, BGN, BCL6, ACVRL1, PLAG1, PLAU, MAPK1, APEX1, RB1, SCN1A, JAK1, SETMAR, SLPI, CETN1, SP3, SRC, SRF, SSX2, STAT3, PECAM1, PDGFRB, PDGFRA, PDGFB, CCK, KRAS, LGALS3, MBD1, MEF2A, MEF2D, MET, MMP2, MRC1, GADD45B, MYLK, PPP1R12A, NME1, NPAS2, NTRK1, ROR2, PCP4, SMARCB1

Drugs

(-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4-(1H-indol-3-yl) pyrrolidine-2, 5-dione, (1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate, 16-base single-stranded peptide nucleic acid oligonucleotide linked to a 7-amino acid peptide, 18-(p-(, 4-oxo-4H-chromene-2-carboxylic acid (2-(2-4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl-2H-tetrazol-5-yl)-4,5-dimethoxy-phenyl)-amide, 7-ethyl-10-hydroxy-camptothecin, Anlotinib, Autologous CD4+ and CD8+ T cells transduced with a lentiviral vector encoding an affinity enhanced T cell receptor specific to MAGE-A4, Autologous CD4+ and CD8+ T cells transduced with lentiviral vector containing an affinity-enhanced T-cell receptor targeting the New York esophageal antigen-1, Brostallicin, Camsirubicin, Crenolanib besylate, Deforolimus, Doxorubicin hydrochloride (liposomal) ( DOXIL ), Doxorubicin(6-maleimidocaproyl)hydrazone, Fenretinide, Fibromun, Genetically modified serotype 5/3 adenovirus coding for granulocyte-macrophage colony-stimulating factor, Human/murine chimeric monoclonal antibody against endoglin, Larotrectinib ( VITRAKVI ), Mammalian target of rapamcyin (mTOR) inhibitor, N-acetylsarcosyl-glycyl-L-valyl-D-allo-isoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl-L-prolyl-N-ethylamide, Olaratumab ( LARTRUVO ), Ombrabulin, Paclitaxel ( TAXOL ), Palifosfamide, Propranolol hydrochloride ( HEMANGEOL ), Sindbis virus envelope pseudotyped lentiviral vector encoding New York oesophageal squamous cell carcinoma-1 protein, Trabectedin ( YONDELIS ), Vinorelbine tartrate, Yttrium (90Y)-DTPA-radiolabelled chimeric monoclonal antibody against frizzled homologue 10

Interested in hearing about new therapies?

A rare soft tissue sarcoma characterized by a malignant space-occupying lesion most commonly located in the retroperitoneum or the inferior vena cava, but also other soft tissues, and composed of cells showing distinct features of smooth muscle cells. The tumor presents with mass effect depending on the location. It is capable of both local recurrence and distant metastasis, while lymph node metastasis is rare. Prognosis largely depends on tumor location and size.